Genomics Raises News Today

C2i Genomics launches its C2inform minimal residual disease (MRD) test across Europe, after obtaining CE-IVD marking in the EU, UK and Switzerland

– Funds will be used to accelerate clinical development and commercialization of the company’s C2-Intelligence Platform, a cancer diagnostics service, that uses AI pattern recognition and whole-genome analysis to provide rapid and cancer-specific detection of residual disease 100x more sensitive than legacy platforms. – C2i Genomics also plans to use financing to strengthen partnerships with pharmaceutical companies and accelerate development of novel oncology drugs and pursue regulatory ...